Skip to main content
. 2020 Nov 13;7:542485. doi: 10.3389/fcvm.2020.542485

Figure 7.

Figure 7

Pharmacological inhibition of p90RSK reduces tumor vessel permeability without altering vascular structure or tumor growth. (A) Experimental scheme of mouse experiment. (B) A673 Ewing sarcoma orthotopic tumor volumes were plotted over time (means ± SEM, n = 10 mice/treatment). (C–F) Tumor vasculature structural analysis was performed by quantifying number of vessels, average vessel length, number of vessels >100 um, number of open lumens, and microvessel density in 5 random fields/tumor (means ± SEM, n = 10/group). Statistical significance was assessed using student's t-test. (G) Representative images of FITC-dextran (green), CD31 (red), and DAPI (blue) immunofluorescence. (H,I) Tumor vessel permeability was compared between treatment groups using dextran:CD31 quantification (means ± SEM, n = 10/group). Statistical significance was assessed using student's t-test. *P < 0.05, **P < 0.01, ***P < 0.001.